Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle–Associated PDGFRβ()

Treatment of BRAF mutant melanoma with kinase inhibitors has been associated with rapid tumor regression; however, this clinical benefit is short-lived, and most patients relapse. A number of studies suggest that the extracellular environment promotes BRAF inhibitor resistance and tumor progression....

Descripción completa

Detalles Bibliográficos
Autores principales: Vella, Laura J., Behren, Andreas, Coleman, Bradley, Greening, David W., Hill, Andrew F., Cebon, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678363/
https://www.ncbi.nlm.nih.gov/pubmed/28963969
http://dx.doi.org/10.1016/j.neo.2017.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678363/
https://www.ncbi.nlm.nih.gov/pubmed/28963969
http://dx.doi.org/10.1016/j.neo.2017.07.002

Ejemplares similares